RU2465270C3 - Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она - Google Patents

Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она

Info

Publication number
RU2465270C3
RU2465270C3 RU2009109068A RU2009109068A RU2465270C3 RU 2465270 C3 RU2465270 C3 RU 2465270C3 RU 2009109068 A RU2009109068 A RU 2009109068A RU 2009109068 A RU2009109068 A RU 2009109068A RU 2465270 C3 RU2465270 C3 RU 2465270C3
Authority
RU
Russia
Prior art keywords
ftalazin
flutorbenzyl
cyclopropankarbonylpiperazin
carbonyl
polymorphic form
Prior art date
Application number
RU2009109068A
Other languages
English (en)
Other versions
RU2009109068A (ru
RU2465270C2 (ru
Original Assignee
Кудос Фармасеутикалс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38952365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2465270(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кудос Фармасеутикалс Лимитед filed Critical Кудос Фармасеутикалс Лимитед
Publication of RU2009109068A publication Critical patent/RU2009109068A/ru
Application granted granted Critical
Publication of RU2465270C2 publication Critical patent/RU2465270C2/ru
Publication of RU2465270C3 publication Critical patent/RU2465270C3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
RU2009109068A 2006-10-17 2007-10-15 Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она RU2465270C3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82969406P 2006-10-17 2006-10-17
US60/829,694 2006-10-17

Publications (3)

Publication Number Publication Date
RU2009109068A RU2009109068A (ru) 2010-11-27
RU2465270C2 RU2465270C2 (ru) 2012-10-27
RU2465270C3 true RU2465270C3 (ru) 2017-03-28

Family

ID=38952365

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009109068A RU2465270C3 (ru) 2006-10-17 2007-10-15 Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она

Country Status (35)

Country Link
US (2) US7692006B2 (ru)
EP (3) EP2374800A3 (ru)
JP (3) JP5248513B2 (ru)
KR (2) KR101494910B1 (ru)
CN (3) CN104649979B (ru)
AR (1) AR063320A1 (ru)
AT (1) ATE528296T1 (ru)
AU (1) AU2007311766B2 (ru)
BR (1) BRPI0717125B8 (ru)
CA (2) CA2875147C (ru)
CL (1) CL2007002967A1 (ru)
CO (1) CO6210728A2 (ru)
CY (1) CY1112345T1 (ru)
DK (1) DK2064189T3 (ru)
ES (2) ES2587129T3 (ru)
HK (2) HK1126483A1 (ru)
HR (1) HRP20120007T1 (ru)
IL (2) IL197420A (ru)
ME (1) ME01987B (ru)
MX (1) MX2009004103A (ru)
MY (2) MY162829A (ru)
NO (2) NO341963B1 (ru)
NZ (1) NZ575627A (ru)
PE (1) PE20081175A1 (ru)
PL (1) PL2064189T3 (ru)
PT (1) PT2064189E (ru)
RS (1) RS52112B (ru)
RU (1) RU2465270C3 (ru)
SA (2) SA07280551B1 (ru)
SG (2) SG168523A1 (ru)
SI (1) SI2064189T1 (ru)
TW (1) TWI404716B (ru)
UA (1) UA97494C2 (ru)
UY (1) UY30639A1 (ru)
WO (1) WO2008047082A2 (ru)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101484421A (zh) * 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基苯甲酰胺衍生物
WO2007144652A2 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Parp inhibitors
WO2007144637A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HUE027641T2 (en) * 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
MX2010004028A (es) * 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
TW201114756A (en) * 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102485721B (zh) * 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
MX367614B (es) 2012-01-20 2019-08-28 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma.
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
CN105777651A (zh) * 2015-01-13 2016-07-20 江苏豪森药业集团有限公司 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
CN105985294B (zh) * 2015-02-11 2020-12-25 四川科伦药物研究院有限公司 一种奥拉帕尼的制备方法
WO2016165650A1 (zh) * 2015-04-17 2016-10-20 苏州晶云药物科技有限公司 奥拉帕尼与尿素的共晶及其制备方法
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
EP3298005B1 (en) 2015-05-21 2024-01-24 The Regents of The University of California Anti-cancer compounds
CN105439961A (zh) * 2015-06-12 2016-03-30 苏州晶云药物科技有限公司 奥拉帕尼的晶型i及其制备方法
CN105175370A (zh) * 2015-07-27 2015-12-23 安徽万邦医药科技有限公司 一种2-氟-5-[(3-氧代-1(3h)-异苯并呋喃亚基)甲基]苯腈的合成方法
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用
CN106699672B (zh) * 2015-11-16 2019-10-29 上海博邦医药科技有限公司 一种奥拉帕尼无定型物及其制备方法
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
US20170204067A1 (en) * 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
CN105503739B (zh) * 2016-02-24 2018-09-11 合肥启旸生物科技有限公司 一种奥拉帕尼的制备方法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017153958A1 (en) * 2016-03-11 2017-09-14 Lupin Limited Novel polymorphic forms and amorphous form of olaparib
CN107304186B (zh) * 2016-04-25 2021-08-27 杭州容立医药科技有限公司 一种奥拉帕尼的精制方法
CN107304187B (zh) * 2016-04-25 2021-07-09 杭州容立医药科技有限公司 一种奥拉帕尼的重结晶方法
WO2017191562A1 (en) * 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
IL263917B (en) 2016-06-24 2022-07-01 Univ California Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy
EP3263529B1 (en) 2016-06-27 2019-11-06 Xylem Europe GmbH Quartz sleeve support for an uv-lamp
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
CN109563080B (zh) * 2016-08-24 2021-07-30 台湾神隆股份有限公司 奥拉帕尼的制备方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN107098862A (zh) * 2017-06-05 2017-08-29 山东裕欣药业有限公司 一种奥拉帕尼二水合物及其制备方法
CN107325055A (zh) * 2017-08-14 2017-11-07 山东裕欣药业有限公司 一种奥拉帕尼化合物的合成方法
EP3674304B1 (en) * 2017-08-24 2022-04-13 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of parp-1 inhibitor and preparation method therefor
CN108101852A (zh) * 2017-12-27 2018-06-01 山东裕欣药业有限公司 一种奥拉帕尼的制备方法
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
CN111989137A (zh) 2018-01-05 2020-11-24 赛博克萨1公司 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
CN110204530B (zh) * 2018-02-28 2020-05-08 新发药业有限公司 一种瓦他拉尼的制备方法
CN108558773A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种奥拉帕尼药物中间体的制备方法
CN109535082A (zh) * 2018-12-24 2019-03-29 合肥创新医药技术有限公司 一种奥拉帕尼的制备方法
US10703728B1 (en) * 2019-06-18 2020-07-07 Scinopharm Taiwan, Ltd. Crystalline form of olaparib and a process for preparing the same
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
WO2021044437A1 (en) * 2019-09-04 2021-03-11 Cipla Limited Olaparib co-crystals and process of preparation thereof
CN110563703B (zh) * 2019-09-18 2021-04-09 浙江省医学科学院 基于crbn配体诱导parp-1降解的化合物及制备方法和应用
WO2021133886A1 (en) 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
IL297537A (en) 2020-04-28 2022-12-01 Rhizen Pharmaceuticals Ag New compounds useful as poly (adp-ribose) polymerase (parp) inhibitors
CN111995582B (zh) * 2020-07-09 2021-12-03 天津理工大学 一种奥拉帕尼与尿素的共晶及其制备方法
CN111689905B (zh) * 2020-07-22 2021-12-03 天津理工大学 一种奥拉帕尼与马来酸的共晶及其制备方法
WO2022058785A1 (en) * 2020-09-16 2022-03-24 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
CN114249695A (zh) * 2020-09-21 2022-03-29 齐鲁制药有限公司 一种奥拉帕利的新晶型、制备方法及用途
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114539161B (zh) * 2020-11-11 2024-03-29 成都硕德药业有限公司 一种奥拉帕尼-尿素共晶及其制备方法
CN112661733A (zh) * 2020-12-23 2021-04-16 南京方生和医药科技有限公司 奥拉帕利杂质中间体、奥拉帕利杂质及其制备方法
CN112500379B (zh) * 2020-12-23 2024-01-23 南京方生和医药科技有限公司 一种奥拉帕利中间体及奥拉帕利的制备方法
CA3207488A1 (en) 2021-01-08 2022-07-14 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
CN113636979B (zh) * 2021-08-12 2023-06-13 天津理工大学 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用
KR102645122B1 (ko) 2021-08-25 2024-03-07 주식회사 보령 올라파립의 제조방법
CN115448886A (zh) * 2022-10-11 2022-12-09 福建福瑞明德药业有限公司 一种奥拉帕利的制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US4665181A (en) 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
ATE60598T1 (de) 1985-11-11 1991-02-15 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
EP0355750B1 (en) 1988-08-19 1995-01-25 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
EP0389995B1 (en) 1989-03-28 1995-05-31 Nisshin Flour Milling Co., Ltd. Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
AU5455194A (en) 1992-11-02 1994-05-24 Merck & Co., Inc. Substituted phthalazinones as nerotensin antagonists
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
PT705903E (pt) 1994-08-12 2001-11-30 Myriad Genetics Inc Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
ATE209660T1 (de) 1994-08-12 2001-12-15 Myriad Genetics Inc 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
EP0820452B1 (en) * 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
IL120264A0 (en) 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2802297A (en) * 1996-04-18 1997-11-07 Merck & Co., Inc. A method of treating cancer
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
AU1407399A (en) 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6943168B2 (en) 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
PT1206461E (pt) 1999-08-11 2004-09-30 Bristol Myers Squibb Co Processo para a preparacao de um analogo de paclitaxel com carbonato de metilo em c-4
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR20010087401A (ko) 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de) 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
WO2001079184A1 (fr) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Composes de piperazine substitues
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
JP4954426B2 (ja) 2000-06-16 2012-06-13 キュリス，インコーポレイテッド 血管形成調節組成物及び利用
IL155645A0 (en) 2000-10-30 2003-11-23 Kudos Pharm Ltd Phthalazinone derivatives
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
EP2281818A1 (en) 2002-02-19 2011-02-09 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
GB0305681D0 (en) * 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
HUE027641T2 (en) 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
MX2010004028A (es) 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.

Also Published As

Publication number Publication date
NO20171775A1 (no) 2009-05-13
RU2009109068A (ru) 2010-11-27
AU2007311766B2 (en) 2013-02-21
NO20091882L (no) 2009-05-13
EP2374800A3 (en) 2012-02-29
WO2008047082A3 (en) 2008-09-25
NO343063B1 (no) 2018-10-22
KR101494910B1 (ko) 2015-02-23
CN104649979B (zh) 2017-04-12
KR20090085033A (ko) 2009-08-06
DK2064189T3 (da) 2012-01-02
SA07280551B1 (ar) 2011-05-04
CN101528714A (zh) 2009-09-09
CL2007002967A1 (es) 2008-04-18
EP2374800A2 (en) 2011-10-12
PE20081175A1 (es) 2008-11-06
CA2875147A1 (en) 2008-04-24
CN101528714B (zh) 2012-06-06
SA110310666B1 (ar) 2013-10-09
EP2064189B1 (en) 2011-10-12
TWI404716B (zh) 2013-08-11
JP2013136607A (ja) 2013-07-11
CO6210728A2 (es) 2010-10-20
WO2008047082A2 (en) 2008-04-24
EP2824098B1 (en) 2016-06-22
MY147389A (en) 2012-11-30
HRP20120007T1 (hr) 2012-01-31
MY162829A (en) 2017-07-31
HK1126483A1 (en) 2009-09-04
SG168523A1 (en) 2011-02-28
ME01987B (me) 2012-08-31
NZ575627A (en) 2011-09-30
CA2664275C (en) 2015-03-17
TW200825066A (en) 2008-06-16
AR063320A1 (es) 2009-01-21
JP2010506894A (ja) 2010-03-04
JP2015013879A (ja) 2015-01-22
JP5248513B2 (ja) 2013-07-31
BRPI0717125B1 (pt) 2022-02-08
CA2664275A1 (en) 2008-04-24
IL216705A0 (en) 2012-01-31
JP5719471B2 (ja) 2015-05-20
IL197420A (en) 2015-07-30
RS52112B (en) 2012-08-31
US7692006B2 (en) 2010-04-06
SI2064189T1 (sl) 2012-01-31
US20090270617A1 (en) 2009-10-29
CA2875147C (en) 2016-09-06
US20080146575A1 (en) 2008-06-19
NO341963B1 (no) 2018-03-05
ES2587129T3 (es) 2016-10-20
US8247416B2 (en) 2012-08-21
UA97494C2 (en) 2012-02-27
KR20140011425A (ko) 2014-01-28
CN104649979A (zh) 2015-05-27
ES2372630T3 (es) 2012-01-24
MX2009004103A (es) 2009-05-05
RU2465270C2 (ru) 2012-10-27
CY1112345T1 (el) 2015-12-09
ATE528296T1 (de) 2011-10-15
PT2064189E (pt) 2012-01-05
PL2064189T3 (pl) 2012-03-30
AU2007311766A1 (en) 2008-04-24
SG10201408404XA (en) 2015-01-29
HK1203959A1 (en) 2015-11-06
IL216705A (en) 2014-02-27
IL197420A0 (en) 2009-12-24
BRPI0717125A2 (pt) 2013-12-17
JP5607773B2 (ja) 2014-10-15
UY30639A1 (es) 2008-05-31
EP2824098A1 (en) 2015-01-14
EP2064189A2 (en) 2009-06-03
BRPI0717125B8 (pt) 2023-01-10
CN102627611A (zh) 2012-08-08

Similar Documents

Publication Publication Date Title
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0811578A2 (pt) Tetramatos substituídos por 3-(2-alcóxi-fenila)
DK2610258T3 (da) Substituerede piperidindihydrothienopyrimidiner
BRPI0716325A2 (pt) Composição antimicrobianas
DE112007002915A5 (de) Verstelleinrichtung
DK3564240T3 (da) Piperidinmellemprodukter
FR2899479B1 (fr) Composition cicatrisante
ATE524477T1 (de) Aziridinylepothilonverbindungen
DE602007002929D1 (de) Lichtempfindliche Zusammensetzung
ITRA20060072A1 (it) Macchina ginnica
FI20065562A0 (fi) Vertikaalinen yhteysvastuun vaihto
DE502008003324D1 (de) Heteroaryl-substituierte piperidine
BRPI0720224A2 (pt) Arilpirazóis substituídos
SMT201200063B (it) Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici
DK2084443T3 (da) Gennemføring
FI20070364A0 (fi) Nostolaite
FI20065446A0 (fi) Muodostusosa
DE112008001131A5 (de) Hebeeinrichtung
DE112007001747A5 (de) Möbelscharnier
FR2898899B1 (fr) Composition photoreticulable
FI20060012A0 (fi) Laakerikilpi
DK2181990T3 (da) Piperidinderivat
ES1062979Y (es) Maquina descascaradora-separadora

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
ND4A Extension of patent duration

Effective date: 20170328

TK4A Correction to the publication in the bulletin (patent)

Free format text: CORRECTION TO CHAPTER -ND4B- IN JOURNAL 10-2017